BRIEF published on 02/18/2026 at 07:35, 1 month 11 days ago GenSight Biologics Strengthens its Regulatory Team Phase III Trial Regulatory Affairs Key Appointments GenSight Biologics Gene Therapies
BRIEF published on 02/18/2026 at 07:35, 1 month 11 days ago GenSight Biologics Strengthens Regulatory Leadership with Key Appointments Gene Therapy Strategic Appointments GenSight Biologics Retinal Diseases Regulatory Leadership
PRESS RELEASE published on 02/18/2026 at 07:30, 1 month 11 days ago Inside Information / Other news releases GenSight Biologics strengthens Regulatory Affairs & Quality team with two key appointments to support global regulatory strategy and upcoming milestones in gene therapy for retinal diseases Quality Regulatory Affairs GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 02/10/2026 at 07:35, 1 month 19 days ago First Steps of the REVISED Clinical Study on GS010/LUMEVOQ® Clinical Study Gene Therapy GenSight Biologics LUMEVOQ Optic Neuropathy
BRIEF published on 02/10/2026 at 07:35, 1 month 19 days ago GenSight Biologics Begins REVISE Study for GS010 Therapy GenSight Biologics LHON REVISE Study GS010 Therapy 15-20 National Hospital
PRESS RELEASE published on 02/10/2026 at 07:30, 1 month 19 days ago Inside Information / Other news releases 15-20 National Hospital and GenSight Biologics treat first patient in GS010/LUMEVOQ® REVISE Study, for Leber Hereditary Optic Neuropathy. Clinical study supported by ANSM and aiming to enroll 14 patients in France GenSight Biologics LHON GS010/LUMEVOQ REVISE Study 15-20 National Hospital
BRIEF published on 01/29/2026 at 00:26, 2 months ago GenSight Biologics Reports EGM Results Shareholders Capital Increase Extraordinary General Meeting GenSight Biologics Financial Authorizations
PRESS RELEASE published on 01/29/2026 at 00:21, 2 months ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 3 months ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
PRESS RELEASE published on 12/29/2025 at 08:00, 3 months ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
Published on 03/28/2026 at 01:00, 1 day 10 hours ago Battery X Metals Announces Confidential Submission of Amended Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 03/28/2026 at 00:55, 1 day 10 hours ago Notification of Relevant Change to Significant Shareholder
Published on 03/27/2026 at 22:45, 1 day 12 hours ago Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder
Published on 03/27/2026 at 22:30, 1 day 12 hours ago Usha Resources Completes Extended Induced Polarization Survey at the Southern Arm Property
Published on 03/28/2026 at 10:05, 1 day 2 hours ago Hisense Advances a Quiet Green Revolution in Home Entertainment
Published on 03/28/2026 at 08:56, 1 day 3 hours ago Turkiye Garanti Bankasi A.S.: Sale of Garanti Bank S.A. and our public disclosure dated 10.03.2026
Published on 03/28/2026 at 01:42, 1 day 9 hours ago EQS-Adhoc: Raiffeisen Bank International AG: Agreement on the acquisition of Garanti BBVA Group Romania
Published on 03/27/2026 at 21:58, 1 day 13 hours ago Kaufman & Broad SA: Availability of the Universal Registration Document 2025
Published on 03/27/2026 at 20:08, 1 day 15 hours ago EQS-Adhoc: CECONOMY AG: Information on the ongoing public takeover process – uncertainty regarding FDI clearance in Austria
Published on 03/27/2026 at 18:52, 1 day 16 hours ago Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:40, 1 day 16 hours ago 2026 share capital increase reserved for members of the Saint-Gobain Group employee savings plan
Published on 03/27/2026 at 17:53, 1 day 17 hours ago Publication of Carrefour's 2025 Universal Registration Document
Published on 03/27/2026 at 17:45, 1 day 17 hours ago PUBLICATION OF THE UNIVERSAL REGISTRATION DOCUMENT FISCAL YEAR 2025
